LOS ANGELES (KABC) -- New technology that's allowing doctors to pinpoint prostate cancer long before it becomes a threat is now widely available. A former firefighter mentioned how this new imaging ...

One-third of patients with PSA levels below 0.2 ng/mL after radical prostatectomy have recurrent disease identifiable by PSMA PET. More than one-third of patients with PSA levels less than 0.5 ng/mL ...

Prostate-specific membrane antigen (PSMA)-PET/CT imaging identified metastatic prostate cancer in almost half of high-risk cases missed by conventional imaging, a retrospective analysis showed.

What The 2024 NCCN Guidelines Say About... It does if a single state in the U.S. is any indication. In North Carolina, significantly higher rates of prostate cancer recurrence were reported among men ...

As part of its Speaking Out video series, CURE talked to Dr. Brian Keith McNeil, on behalf of ZERO Prostate Cancer, about the role of PSMA-PET Imaging versus PSA. Prostate specific antigen (PSA) is a ...

A new radioactive diagnostic agent for use in prostate cancer has been approved by the US Food and Drug Administration (FDA). The product, Gallium 68 PSMA-11 (Ga 68 PSMA-11), has been approved for ...

PSMA PET scans significantly enhance detection and staging of prostate cancer, improving patient stratification and survival outcomes. Three FDA-approved PSMA PET scans are available, aiding in both ...

IN the fight against prostate cancer, one biomarker is proving to be a game changer. According to Sunway Medical Centre Clinical Head and Nuclear Medicine Physician Associate Professor Dr Tan Teik Hin ...

For years, prostate cancer specialists hit a wall when prostate-specific antigen (PSA) levels crept up after definitive treatment. The cancer was likely back — but where? And to what extent? Bone plus ...

A new study from Denmark shows for the first time that men with biochemically recurrent prostate cancer who undergo PSMA PET/CT before salvage radiotherapy have improved survival rates compared to ...

Gozetotide is a drug for diagnostic application in adults with prostate cancer. It is currently the only diagnostic agent that recognizes PSMA-positive prostate cancer and can therefore identify ...